These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

881 related items for PubMed ID: 23390498

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
    Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U.
    PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
    [Abstract] [Full Text] [Related]

  • 3. High glucose-induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model.
    Pan X, Phanish MK, Baines DL, Dockrell MEC.
    Biosci Rep; 2021 Jun 25; 41(6):. PubMed ID: 34003249
    [Abstract] [Full Text] [Related]

  • 4. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T.
    Am J Physiol Renal Physiol; 2014 Jan 25; 306(2):F194-204. PubMed ID: 24226524
    [Abstract] [Full Text] [Related]

  • 5. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
    Baer PC, Koch B, Freitag J, Schubert R, Geiger H.
    Int J Mol Sci; 2020 Jan 08; 21(2):. PubMed ID: 31936266
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S.
    Horm Metab Res; 2015 Aug 08; 47(9):686-92. PubMed ID: 25611208
    [Abstract] [Full Text] [Related]

  • 9. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y, Breljak D, Onishi A, Batz F, Patel R, Huang W, Song P, Freeman B, Mayoux E, Koepsell H, Anzai N, Nigam SK, Sabolic I, Vallon V.
    Am J Physiol Renal Physiol; 2018 Aug 01; 315(2):F386-F394. PubMed ID: 29412698
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway.
    Yao D, Wang S, Wang M, Lu W.
    Mol Med Rep; 2018 Oct 01; 18(4):3625-3630. PubMed ID: 30132524
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K, Makino H.
    PLoS One; 2014 Oct 01; 9(6):e100777. PubMed ID: 24960177
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules.
    Li J, Liu H, Takagi S, Nitta K, Kitada M, Srivastava SP, Takagaki Y, Kanasaki K, Koya D.
    JCI Insight; 2020 Mar 26; 5(6):. PubMed ID: 32134397
    [Abstract] [Full Text] [Related]

  • 20. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.
    Satou R, Cypress MW, Woods TC, Katsurada A, Dugas CM, Fonseca VA, Navar LG.
    Am J Physiol Renal Physiol; 2020 Jan 01; 318(1):F67-F75. PubMed ID: 31682172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.